eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

Mar 18, 2016, 08:00 ET from eFFECTOR Therapeutics

SAN DIEGO, March 18, 2016 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced the preclinical profile of lead product candidate eFT508 will be presented at a special drug development track session titled "New Drugs on the Horizon 2" at the Annual Meeting of the American Association for Cancer Research, to be held April 16-20, 2016 in New Orleans at the Ernest N. Morial Convention Center.

The presentation, titled "eFT508: An oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2, a novel approach for the treatment of cancer," will be presented by Kevin Webster, Ph.D., senior vice president, cancer biology, eFFECTOR Therapeutics at 4:15 p.m. CT, on Sunday, April 17, 2016, in New Orleans Theater C, Morial Convention Center.

Separately, in an educational session titled "From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 1-- Optimizing Drug Discovery: Insights on an Important Process," Siegfried Reich, Ph.D., senior vice president, research, eFFECTOR Therapeutics, will present the story of the discovery of lead candidate eFT508 in a presentation titled "Leveraging iterative 3D-structure information while managing physicochemical properties, Design of eFT508: An oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2."  The educational session will run from 8:00 a.m.10:00 a.m. CT on Saturday, April 16, 2016, in room 271, Morial Convention Center.

Additionally, in a major symposium entitled "Oncogenic mRNA Translation," company founder Davide Ruggero, Ph.D., Helen Diller Family Chair in Basic Cancer Research, University of California, San Francisco, will broadly discuss the important role of translation control in cancer in a presentation titled "Translation makes an impact: Tailor-made protein expression for metabolism, cancer & disease" at 11:40 a.m. on Tuesday, April 19, in room 265, Morial Convention Center.

About eFFECTOR Therapeutics
eFFECTOR Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's lead drug candidate, eFT508, is a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases that act as signal integrators at the convergence of multiple oncogenic and immune signaling pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery. eFFECTOR has raised $111M in financing from top-tier private and corporate venture funds. For more information, visit www.effector.com.  

Contact 
Heidi Chokeir, Ph.D.
619-849-5377 
heidi@canalecomm.com

Logo - http://photos.prnewswire.com/prnh/20150619/224279LOGO  

 

SOURCE eFFECTOR Therapeutics



RELATED LINKS

http://www.effector.com